Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans

8/31/2026

Fact Sheets

View Original

Action Summary

MFN Pricing Agreements: Announced nine new deals with mid-sized pharmaceutical manufacturers—Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB—to provide the lowest prices paid by developed nations, bringing MFN coverage to 89% of the branded drug market.
Cost Savings for Americans: The agreements aim to lower prescription drug costs, with estimated savings of $600 billion over the next decade; additional efforts through the TrumpRx program have already saved over $700 million and significantly reduced costs for senior citizens.
Supply Chain and Manufacturing Investments: The nine companies committed to invest at least $19.6 billion in U.S. manufacturing and are donating active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to ensure a secure supply in emergencies.
Historical Policy Milestones: Key actions include a May 12, 2025, Executive Order on MFN pricing, subsequent directives to leading manufacturers, the first MFN deal with Pfizer on September 30, 2025, and the launch of TrumpRx.gov on February 5, 2026, to facilitate discounted access to medicines.
Congressional Call to Action: President Trump is urging Congress to pass the Great Healthcare Plan, which aims to lower drug prices, reduce insurance premiums, increase price transparency, and hold insurance companies accountable.

Risks & Considerations

The announcement of MFN pricing agreements could lead to significant changes in the pharmaceutical landscape, which may impact Vanderbilt University’s research programs in health and medicine. As prices lower, it may alter funding dynamics for pharmaceutical research.
There is a risk that these agreements may lead to a reduction in investment in drug research and development from pharmaceutical companies, which could limit future partnerships for Vanderbilt’s medical research initiatives.
As drug prices drop, there might be a shift in patient demographics and needs that could affect the university’s healthcare programs, particularly those associated with its medical center.
The emphasis on lowering drug prices could spark a debate around healthcare access and equity, which may require Vanderbilt to adjust its community health outreach efforts to align with new public expectations.

Impacted Programs

Vanderbilt University Medical Center may see increased patient volume due to lower drug prices, requiring adjustments in service delivery and capacity planning.
Pharmacy and Pharmaceutical Sciences Programs may need to adapt their curricula to include more about drug pricing dynamics and policy advocacy.
Research initiatives at Vanderbilt’s Center for Health Services Research could benefit from new funding opportunities related to studies on drug pricing impacts on healthcare delivery.

Financial Impact

Vanderbilt could experience shifts in research funding as pharmaceutical companies focus on complying with MFN pricing rather than investing in new projects.
Potential lower drug costs could lead to increased access for patients, possibly resulting in a higher number of patients utilizing Vanderbilt’s healthcare services.
If healthcare costs decrease significantly, Vanderbilt may need to reevaluate its financial aid strategies for students in health-related fields, as the financial landscape for healthcare providers may change.

Relevance Score: 4 (The order presents a need for potential major changes or transformations of programs.)

Key Actions

The School of Medicine should collaborate with pharmaceutical companies involved in the MFN agreements to explore opportunities for research and clinical trials. This partnership can enhance the university’s reputation in the pharmaceutical field and contribute to innovative treatments for chronic and rare diseases.
Vanderbilt’s Health Policy Research Center should analyze the implications of the MFN pricing model on healthcare affordability and access. This research can provide insights into how these changes impact healthcare delivery and inform policy recommendations aimed at improving patient outcomes.
The Center for Biomedical Ethics should engage in discussions regarding the ethical implications of drug pricing and access under the new MFN agreements. This will position Vanderbilt as a leader in addressing moral questions surrounding healthcare equity and pharmaceutical innovation.
Vanderbilt’s Public Health Department should monitor the effects of lowered drug prices on public health outcomes and disparities. Engaging with local communities to assess the impact of these changes can guide future public health initiatives.
The Office of Federal Relations should advocate for ongoing support and funding related to drug pricing initiatives at the federal level, ensuring Vanderbilt remains aligned with national healthcare priorities and can influence future policies.

Opportunities

The executive order provides a unique opportunity for Vanderbilt’s Center for Pharmaceutical Policy to engage in policy analysis regarding the impact of MFN pricing on drug affordability and access, potentially influencing future federal initiatives.
The focus on drug price reductions can lead to collaborative research projects between Vanderbilt and pharmaceutical companies, enhancing the university’s role in drug development and health innovation.
There is potential for Vanderbilt’s Center for Health Services Research to evaluate the effectiveness of the MFN agreements, providing valuable data on patient outcomes and cost savings that could inform future healthcare policies.
The significant savings projected from the MFN deals may present funding opportunities for Vanderbilt’s Health Economics Program to study the broader economic impacts of drug pricing reforms on healthcare systems.
Engaging with patients and community stakeholders about their experiences with drug pricing changes can enhance Vanderbilt’s community outreach and position it as a trusted advocate for healthcare equity.

Relevance Score: 4 (The executive order necessitates major process changes in how Vanderbilt engages with pharmaceutical pricing and healthcare policy.)

Average Relevance Score: 3.2

Timeline for Implementation

N/A – Although the summary lists several announcement dates, no explicit deadlines or compliance periods are provided for the directives.

Relevance Score: 1

Impacted Government Organizations

Office of the United States Trade Representative (USTR): This office is highlighted for its role in international negotiations, as evidenced by the joint announcement with other agencies affecting drug pricing policies and foreign pricing agreements.
Department of Commerce: Mentioned as a key partner in the announcement with the USTR and HHS, the Department of Commerce is involved in implementing trade-related and economic aspects of the drug pricing strategy.
Department of Health and Human Services (HHS): HHS plays a central role in the management and oversight of drug pricing policies and ensuring that State Medicaid programs have access to MFN drug prices.
State Medicaid Programs: Every State Medicaid program is directly impacted through the implementation of MFN pricing, ensuring billions in savings and expanding benefits to the most vulnerable populations.
Council of Economic Advisers: The Council is referenced for its role in providing economic analysis, such as estimating the projected savings from these agreements, thereby influencing policy decisions.
Strategic Active Pharmaceutical Ingredients Reserve (SAPIR): Although a specialized reserve, SAPIR is functionally a government-managed inventory system that receives contributions from the pharmaceutical companies, enhancing domestic drug supply security.

Relevance Score: 3 (A medium number of Federal and state-level agencies and entities are impacted by the directive.)

Responsible Officials

Office of the United States Trade Representative – Tasked with implementing trade-related aspects and international agreements (such as the U.K. agreement) as part of the directive.
Department of Commerce – Responsible for contributing to trade and economic policy measures linked to the pricing and market reforms outlined in the Executive Order.
Department of Health and Human Services – Charged with overseeing actions to lower prescription drug prices and ensure broad access, in line with the MFN pricing initiative.

Relevance Score: 4 (The directives involve high-level agency heads responsible for critical trade and health policy implementation.)